Myriad Announces Inclusion of Prolaris(R) Test in NCCN

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Myriad Announces Inclusion of Prolaris(R) Test in NCCN Guidelines

SALT LAKE CITY, Oct. 27, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq: MYGN ) today announced that its Prolaris test has been included in the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines) for all men with localized prostate cancer, regardless of their risk category. The NCCN guidelines provide treatment recommendations to ensure that patients receive diagnostic treatment and services that are likely to improve clinical outcomes.

Specifically, the updated NCCN guidelines include the use of the Prolaris test to help patients better assess their risk of disease specific mortality and biochemical recurrence. Importantly, Prolaris is supported by seven peer-reviewed publications and is the first and only genetic test for prostate cancer that is:

  • Proven and validated based on gold standard clinical endpoints of disease recurrence and prostate cancer-specific death in untreated men, thus identifying men who can safely forgo initial surgery or radiation and be managed with active surveillance;
  • Proven in clinical utility studies to change treatment recommendations for up to 65 percent of prostate cancer patients in all risk categories, which may enhance adherence to recommended treatments; and
  • To receive a draft local coverage determination (LCD) for Medicare reimbursement for low-risk patients.

"We are excited that the NCCN has included Prolaris as an important prognostic test to help inform men with localized prostate cancer about the aggressiveness of their disease and to help their physicians tailor therapy based on a more accurate assessment of risk," said Chip Parkinson, general manager of the Urology Business Unit at Myriad. "Prolaris is the only test proven to accurately predict mortality in men with localized prostate cancer, and the only biomarker validated in studies of patients who were untreated. This means that men can be confident in choosing active surveillance with Prolaris."

Earlier this month, Myriad announced that Palmetto GBA, the Medicare administrative contractor, issued a draft LCD for the Prolaris test for patients with low-risk prostate cancer. Once finalized, the LCD will establish coverage policy for Medicare beneficiaries throughout the United States.

About Prolaris ®

Prolaris is a novel 46-gene RNA-expression test that directly measures tumor cell growth characteristics for stratifying the risk of disease progression in prostate cancer patients. Prolaris provides a quantitative measure of the RNA expression levels of genes involved in the progression of tumor growth. Low gene expression is associated with a low risk of disease progression in men who may be candidates for active surveillance and high gene expression is associated with a higher risk of disease progression in patients who may benefit from additional therapy. For more information visit: www.prolaris.com .

About Myriad Genetics

Myriad Genetics is a leading molecular diagnostic company dedicated to making a difference in patients' lives through the discovery and commercialization of transformative tests to assess a person's risk of developing disease, guide treatment decisions and assess risk of disease progression and recurrence. Myriad's molecular diagnostic tests are based on an understanding of the role genes play in human disease and were developed with a commitment to improving an individual's decision making process for monitoring and treating disease. Myriad is focused on strategic directives to introduce new products, including companion diagnostics, as well as expanding internationally. For more information on how Myriad is making a difference, please visit the Company's websites: www.myriad.com .

Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, myRisk Hereditary Cancer, myChoice, myPlan Lung Cancer, BRACAnalysis CDx, HRD, Vectra and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. in the United States and foreign countries. MYGN-F, MYGN-G

Safe Harbor Statement

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the inclusion of the Prolaris test in the NCCN guidelines for all men with localized prostate cancer, regardless of their risk category; the NCCN guidelines providing treatment recommendations to ensure that patients receive diagnostic treatment and services that are likely to improve clinical outcomes; the use of the Prolaris test to help patients and their physicians better assess their risk of disease specific mortality and biochemical recurrence; the ability of the Prolaris test to predict prostate cancer-specific disease progression; the ability of the Prolaris test to identify men who can safely forgo initial surgery or radiation and be managed with active surveillance; the ability of the Prolaris test to change treatment recommendations for up to 65 percent of prostate cancer patients in all risk categories, which may enhance adherence to recommended treatments; the CMS draft local coverage determination for the Prolaris test, and the scope, timing and effectiveness of a final local coverage determination; the Prolaris testing being the only test to accurately predict clinical outcomes or influence treatment plans for patients; and the Company's strategic directives under the caption "About Myriad Genetics." These "forward-looking statements" are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by forward-looking statements. These risks and uncertainties include, but are not limited to: the risk that sales and profit margins of our existing molecular diagnostic tests and pharmaceutical and clinical services may decline or will not continue to increase at historical rates; risks related to our ability to transition from our existing product portfolio to our new tests; risks related to changes in the governmental or private insurers reimbursement levels for our tests or our ability to obtain reimbursement for our new tests at comparable levels to our existing tests; risks related to increased competition and the development of new competing tests and services; the risk that we may be unable to develop or achieve commercial success for additional molecular diagnostic tests and pharmaceutical and clinical services in a timely manner, or at all; the risk that we may not successfully develop new markets for our molecular diagnostic tests and pharmaceutical and clinical services, including our ability to successfully generate revenue outside the United States; the risk that we may not be successful in transitioning from our existing product portfolio to our new products, such as our myRisk Hereditary Cancer test, which represents the next generation of our existing hereditary cancer franchise; the risk that we may not be able to generate sufficient revenue from our existing tests and our new tests or develop new tests; the risk that licenses to the technology underlying our molecular diagnostic tests and pharmaceutical and clinical services and any future tests are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with manufacturing our products or operating our laboratory testing facilities; risks related to public concern over genetic testing in general or our tests in particular; risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; risks related to our ability to obtain new corporate collaborations or licenses and acquire new technologies or businesses on satisfactory terms, if at all; risks related to our ability to successfully integrate and derive benefits from any technologies or businesses that we license or acquire; risks related to increased competition and the development of new competing tests and services; risks related to our projections about the potential market opportunity for our products; the risk that we or our licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying our tests; the risk of patent infringement claims or challenges to the validity of our patents; risks related to changes in intellectual property laws covering our molecular diagnostic tests and pharmaceutical and clinical services and patents or enforcement in the United States and foreign countries, such as the Supreme Court decision in the lawsuit brought against us by the Association for Molecular Pathology et al; risks of new, changing and competitive technologies and regulations in the United States and internationally; and other factors discussed under the heading "Risk Factors" contained in Item 1A in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. All information in this press release is as of the date of the release, and Myriad undertakes no duty to update this information unless required by law.

Media Contact: Ron Rogers (801) 584-3065 Investor Contact: Scott Gleason (801) 584-1143

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Visual Cipher Bench Exposes AI Agents' Hidden Rule Gap

Updated Category News Views 0

Forty little black-and-white puzzles just threw a bucket of cold water on the autonomous-agent sales pitch. Einsia AI’s Navers Lab says its new Visual Cipher Bench found that the best result among eight frontier models was only 26.7%, with no tested configuration clearing 30%. That is not a minor blemish. It is a reminder that a model can sound clever, use tools, and...

Continue Reading
Lake Ridge's Strong Quarter Meets a Book Value Hit

Updated Category News Views 105

An $8.25-per-share securities markdown is the splinter in an otherwise sturdy third-quarter report from Lake Ridge Bancorp. The bank earned $9.8 million, or $4.97 per common share, for the quarter ended September 30, 2026. That is up from $9.0 million, or $4.59 per share, in the prior quarter and $7.7 million, or $3.94 per share, a year earlier. Those are not flimsy...

Continue Reading
Makers Nutrition Credit Puts a Clock on New Brands

Updated Category News Views 222

A few cents per bottle can look downright beautiful when a new supplement brand is staring at its first production bill. Makers Nutrition announced on November 17 a Black Friday manufacturing-credit offer aimed at entrepreneurs and established sellers launching a new formulation, with qualifying new orders eligible for as much as $0.45 per unit through November 29, 2026....

Continue Reading
Universal Haptics Protocol May Cut Integration Friction

Updated Category News Views 301

A controller rumbling at the wrong moment is a small annoyance, but the plumbing behind that rumble has been a stubborn mess for years. The Haptics Industry Forum's Universal Haptics Protocol 1.0, announced November 17, 2026, is an attempt to clean up that mess with a shared language between software and touch-feedback hardware. This is not the sort of release that sends...

Continue Reading
Thoughts Unleashed Arrives With a Personal American Voice

Updated Category News Views 139

A lifetime of observation finally gets its own page Forty is an unusual age to begin writing poetry, which is exactly why Joyce Ann Grooms McGeehan's debut has a little more texture than the usual polished promise of inspiration. Thoughts Unleashed by an Independent, American Woman comes from someone who spent decades teaching French, English, and ESL, then retired to a...

Continue Reading
A Decade of Giving: Light the World Initiative's Impact

Updated Category News Views 131

The Red Kiosk Revolution It's not every day that a church initiative pops up in global conversations, but here we are—ten years into the Light the World initiative by The Church of Jesus Christ of Latter-day Saints. What's interesting is how these little kiosks, like silent ambassadors, have become a staple in 145 spots this holiday season, spanning continents. Each...

Continue Reading
LG Channels UAE Push Tests the Free Streaming Model

Updated Category News Views 11

A television's idle screen is turning into contested real estate in the UAE. LG Channels is adding programming from Rakuten TV, Stingray and Red Bull TV to its free, ad-supported service, and that matters for more than somebody hunting a movie after dinner. This is a practical push to make webOS-powered screens more useful, more frequently used and, eventually, more...

Continue Reading
Trilith Holiday Tour Blends Film Access and Giving

Updated Category News Views 53

Snow machines, trolley rides, and a mental-health subsidy are sharing the same stage in Fayetteville this holiday season. That is an unusual mix, but it fits Trilith Foundation’s stated mission better than another generic lights-and-cocoa event ever could. From Nov. 21 through Dec. 31, the Foundation is turning its guided Trilith Studios tour into a seasonal experience...

Continue Reading
Holiday Grease Advice Shows Utility Work Up Close Today

Updated Category News Views 117

Butter and pan drippings are mundane right until they become a backed-up kitchen line on a crowded holiday afternoon. New Jersey American Water's Nov. 17, 2026 reminder is not glamorous utility news, and frankly it is not trying to be. It is a practical warning: fats, oils and grease can cool, harden and accumulate in household pipes and farther along the wastewater...

Continue Reading
Vertex Extends Genomics Pact With $220M in Potential

Updated Category News Views 49

Eight years is long enough to separate a useful science partner from a glossy slide deck, and Vertex’s decision to add four more years with Genomics deserves attention. This is not a splashy acquisition, nor is it a clean revenue number investors can plug into next quarter’s model. It is a deeper commitment to the slow, expensive, wonderfully unforgiving business of...

Continue Reading

Top 5 Most Recently Viewed Articles

Breaking News: Sportswear Highlights and Streaming Drama Unfolds

Updated Category News Views 235

New On The Block Puma SE, a Germany-based sportswear company, is drawing interest from several buyers in Asia. Notable bids are coming from China's Anta Sports and Li Ning Co., alongside Japan's Asics Corp. As the market responds to this potential sale, the implications for both Puma and the interested firms may shift the dynamics in the sportswear industry. The Netflix...

Continue Reading
Bridging the AI Adoption Gap for Modern Enterprises

Updated Category News Views 103

Navigating the Challenges of AI Adoption in Enterprises In today's fast-paced business landscape, the integration of artificial intelligence (AI) has become more crucial than ever. A recent survey conducted by Unily highlights a pressing concern: many enterprises are struggling to keep pace with AI adoption. The findings reveal that nearly 40% of employees feel their...

Continue Reading
Cryptocurrency Market Trends: Key Insights on Bitcoin and More

Updated Category News Views 393

Cryptocurrency Market Holds Steady Amid Economic Shifts Recently, the cryptocurrency market has shown remarkable stability despite fluctuating stock indices. As economic factors shift, particularly with recent job data revisions, market expectations for interest rate changes have intensified. Bitcoin Sees Minor Decline Bitcoin momentarily surged past $113,000 before...

Continue Reading
Exploring Earnings Insights for Stantec's Upcoming Report

Updated Category News Views 77

Stantec's Upcoming Earnings Report Overview Stantec (NYSE: STN) is preparing to release its latest quarterly earnings report soon. Investors are gearing up in anticipation of what this report might reveal about the company's financial health and future outlook. Analysts' Earnings Predictions Experts are estimating that Stantec will announce an earnings per share (EPS) of...

Continue Reading
Yarbo Unleashes the M Series: Transforming Yard Care

Updated Category News Views 45

Dust off your lawn chairs, folks, because Yarbo is strutting into IFA 2026 with its M Series, a real game-changer in yard robotics. These aren't just fancy grass clippers; they're smart machines turning yard care on its head. Ever wrestle with a rake or push a lawn mower when you'd rather be soaking in some sun? Well, you're in luck. From Dream to Dirt: M Series Arrives...

Continue Reading